Gilead has agreed to acquire global rights to PepStar Therapeutics’ IL-23 receptor inhibitor program, including HCXT-2001, in a deal valued at $1.275 billion upfront cash, although one source described the payment as $1.3 billion. The asset is only in phase 1, making the size of the check the central fact: Gilead is paying a late-stage price for a very early oral inflammation program because it sees strategic value in the target, the modality and the fit with its existing pipeline.
HCXT-2001 is an oral macrocyclic peptide inhibitor of the IL-23 receptor. Gilead Chief Medical Officer Dietmar Berger said the company sees potential for HCXT-2001 alone or in combination, including with emvistegrast, as a daily oral treatment for people living with inflammatory bowel disease. That makes the transaction less a standalone asset buy than an attempt to assemble an all-oral immunology and inflammatory platform.
The asset and why it matters
PepStar’s program targets IL-23R, a pathway already clinically validated in immune-mediated diseases. The commercial backdrop is established: AbbVie’s injectable Skyrizi generated nearly $10 billion in the first half of the year, while Johnson & Johnson has promoted the launch of oral IL-23 drug Icotyde without sharing sales data.
HCXT-2001 is entering that same therapeutic logic from the oral side. Icotyde is approved for plaque psoriasis, while Skyrizi’s label covers plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. BioSpace reported that Gilead hopes HCXT-2001 will have a future in psoriasis as well, while Berger specifically highlighted IBD.
The differentiating hypothesis appears to be pharmacology plus regimen design. According to Fierce, PepStar extended the half-life of HCXT-2001, and the first phase 1 trial could test daily and weekly administration in the multiple-ascending-dose portion. BMO Capital Markets said less frequent dosing and the possibility of combining the peptide with emvistegrast could represent key points of differentiation.
The development picture
HCXT-2001 remains early. Fierce reported that researchers added one HCXT-2001 study to China’s clinical trial registry in August and uploaded a second study the following month. Both are enrolling healthy volunteers and assessing the effect of food. The second study is evaluating single doses of “HCXT-2001 Tablets (A).” A third study in New Zealand is testing “HCXT-2001 Tablets” and “HCXT-2001 Tablets (A)” in healthy adults.
Food-effect work is not a side issue for this class. Fierce noted that patients must wait at least 30 minutes after taking Icotyde before eating, and Merck & Co.’s Lipfendra carries the same restriction. As J&J has shown, oral macrocyclic peptides can survive the gut and engage targets usually addressed by injectables, but absorption can still be operationally limiting. For Gilead, any dosing convenience advantage would matter commercially as much as raw efficacy.
The portfolio signal
The transaction also extends Gilead’s broader effort to diversify beyond HIV and build a durable inflammation business. Emvistegrast has become a focal point of that strategy, and BioSpace said analysts viewed its recent phase 2 ulcerative colitis data as validation of the company’s immunology and inflammatory push.
BMO called the PepStar deal a logical complement to emvistegrast that sets up a potential all-oral combination. That framing helps explain why Gilead was willing to spend so aggressively before proof-of-concept efficacy data are available. The company is not just buying entry into IL-23R; it is buying optionality around how multiple oral mechanisms could be combined.
The structure is notable in another way. BioSpace pointed out that drugmakers have been doing many deals in China, but those transactions are typically licensing agreements rather than outright acquisitions of rights on this scale. The deal is expected to close by the end of the quarter.
